Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
May 22 2008 - 4:05PM
PR Newswire (US)
SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) will be presenting at the FBR Capital Markets
Investor Conference in New York on Wednesday, May 28, 2008 at 9:45
a.m. ET / 6:45 a.m. PT. David M. Kendall, M.D., Executive Director,
Medical Affairs of Amylin Pharmaceuticals, will be providing a
corporate overview. The live presentation and breakout session will
be webcast, and a recording will be made available following the
event. The webcast and recording will be accessible through
Amylin's corporate website, located at http://www.amylin.com/. To
access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software. About Amylin
Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Amylin
has developed and gained approval for two first- in-class medicines
for diabetes, SYMLIN(R) (pramlintide acetate) injection and
BYETTA(R) (exenatide) injection. Amylin's research and development
activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin
is headquartered in San Diego, California with over 1,900 employees
nationwide. Further information on Amylin Pharmaceuticals is
available at http://www.amylin.com/. DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Michael York, Senior Director,
Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200
x8602 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024